CN Patent

CN105899232A — 用于增强免疫应答的mTOR抑制剂

Assigned to Novartis AG · Expires 2016-08-24 · 10y expired

What this patent protects

本发明部分地涉及通过部分mTOR抑制用于增强免疫应答的组合物和方法，例如，使用低、免疫增强剂量的mTOR抑制剂，如RAD001。

USPTO Abstract

本发明部分地涉及通过部分mTOR抑制用于增强免疫应答的组合物和方法，例如，使用低、免疫增强剂量的mTOR抑制剂，如RAD001。

Drugs covered by this patent

Patent Metadata

Patent number
CN105899232A
Jurisdiction
CN
Classification
—
Expires
2016-08-24
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.